Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|October 1, 2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaAgathoclis Agathocleous, Ama Rohatiner, Simon Rule, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow TransplantationGordon Cook, Graeme M Smith, Keiren Kirkland, et al.
British Journal of Haematology|December 19, 2018
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphomaSimon Rule, Gordon Cook, Nigel H Russell, et al.
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
F1000Research|October 23, 2020
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialAndrew Davies, Sharon Barrans, Cathy Burton, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|October 1, 2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaAgathoclis Agathocleous, Ama Rohatiner, Simon Rule, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow TransplantationGordon Cook, Graeme M Smith, Keiren Kirkland, et al.
British Journal of Haematology|December 19, 2018
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphomaSimon Rule, Gordon Cook, Nigel H Russell, et al.
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
F1000Research|October 23, 2020
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialAndrew Davies, Sharon Barrans, Cathy Burton, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Pageof 8